Merck

(Image: Getty/Golubovy)

Top five stories from September

By Ben Hargreaves

The news most interesting to our readers were those featuring collaborations, whether in the production of an Ebola vaccine, biosimilars entering new markets or creating new manufacturing modalities.

(Image: Getty/Esben_H)

Vaccine investment breathing new life into space?

By Ben Hargreaves

Once a neglected area of pharma research, companies are now investing heavily after several major commercial successes and with promising new avenues of research progressing.

(Image: Getty/Monsitj)

Sales of Keytruda leads Merck to strong Q2

By Ben Hargreaves

Sales of immunotherapy treatment, Keytruda, were up by 58% year-on-year, which led Merck to a sales increase of 12% overall compared to 2018.

(Image: Getty/Evgeny_D)

FDA approves the entrance of two biosimilars

By Ben Hargreaves

US FDA gives approval to Samsung Bioepis’ Humira biosimilar and Pfizer’s Rituxan biosimilar, as the number of such medicines gaining entry onto the US market steadily increases.